ARCHIVES

Xeloda, Taxotere, Herceptin Combination May Benefit Invasive Breast Cancer

This article is from The Cancer Letter archive.

Vol. 31 No. 1 | January 25, 2008

Download PDF Visit The Full Archive

Related Articles

AACR Urges FDA to Regulate High Risk Lab-Developed Tests

September 12, 2014

Aranesp Approval Introduces Competition To $1.8 Billion U.S. Cancer Anemia Market

August 2, 2002

CCOP Review Committee Member Objects To “Unwarranted Criticism”

March 4, 1988

Patient Advocacy: Prostate Cancer Agenda Didn’t Include NCI Plans, Lausner Says

November 29, 1996

Cancer Groups Criticize FDA For Ignoring Expert Advice.

November 24, 2000

CCIRC Reviews Two Existing, One Prospective Cooperative Group

March 4, 1977